Journal article
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
- Abstract:
-
Background
Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.
Methods
In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatm...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
GlaxoSmithKline
More from this funder
Bibliographic Details
- Publisher:
- Massachusetts Medical Society Publisher's website
- Journal:
- New England Journal of Medicine Journal website
- Volume:
- 376
- Issue:
- 20
- Pages:
- 1921-1932
- Publication date:
- 2017-05-18
- Acceptance date:
- 2017-02-28
- DOI:
- EISSN:
-
1533-4406
- ISSN:
-
0028-4793
- Pmid:
-
28514601
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:695712
- UUID:
-
uuid:61cac6b3-54a9-4af8-99ca-82209d81bfff
- Local pid:
- pubs:695712
- Source identifiers:
-
695712
- Deposit date:
- 2018-06-13
Terms of use
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 Massachusetts Medical Society. This is the published version of the article. This is also available online from Massachusetts Medical Society at: http://dx.doi.org/10.1056/NEJMoa1702079
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record